NAD+ and Sirtuins for Brain Health: New Science Changes Everything

SNIPPET: New research reveals that brain NAD+ regulation operates through a distinct astrocyte-driven pathway (REV-ERBα–NFIL3–CD38), not the NAMPT mechanism assumed from cardiac studies. NR and NMN boost circulatory NAD+ comparably via gut microbial conversion to nicotinic acid, while SIRT2 activation broadly suppresses age-related neuroinflammation — positioning the NAD+/sirtuin axis as a leading neuroprotective target.

THE PROTOHUMAN PERSPECTIVE#

The NAD+ conversation has been stuck in a loop for years: take NMN or NR, raise your levels, slow aging. Simple narrative. But the brain — the organ we should care about most — doesn't play by the same metabolic rules as your liver or heart. That's the critical update.

What we're seeing now is a fundamental rethinking of how NAD+ is regulated in neural tissue, and it centers on astrocytes — the brain's support cells that most biohackers have never heard of. The REV-ERBα–CD38 pathway identified by Musiek's group at Washington University flips what we thought we knew. Meanwhile, a head-to-head human trial in Nature Metabolism finally settles the NR vs. NMN debate (spoiler: it's a draw, and the gut microbiome is doing the heavy lifting). And the sirtuin family — particularly SIRT2 — is emerging as a master switch for the chronic inflammation that degrades brain function decades before a dementia diagnosis.

For anyone optimizing for cognitive longevity, these findings demand a protocol update. The old "just take NAD+ precursors" approach was incomplete. The new picture involves circadian biology, gut health, and targeted sirtuin activation.

THE SCIENCE#

Brain NAD+ Doesn't Follow the Rules You Think#

Here's where it gets complicated. For years, the assumption was straightforward: REV-ERBα, a circadian nuclear receptor, drives NAD+ production by controlling NAMPT — the rate-limiting enzyme in NAD+ synthesis. That's true in cardiac tissue. It is emphatically not true in the brain.

Lee et al. (2025), publishing in Nature Aging, demonstrated that REV-ERBα controls brain NAD+ through a completely different mechanism: suppression of the NAD+-consuming enzyme CD38 via NFIL3, primarily in astrocytes^[1]. The effect on brain NAD+ is actually the opposite of what happens in the heart. Deleting REV-ERBα in astrocytes increased brain NAD+ and — this is the part that matters — prevented tauopathy in P301S transgenic mice, a well-established Alzheimer's model.

Wait, let me be more precise here. The pathway is REV-ERBα → NFIL3 → CD38. REV-ERBα represses NFIL3, which normally suppresses CD38. So when REV-ERBα is active, CD38 runs unchecked, consuming NAD+. Remove REV-ERBα from astrocytes, and CD38 gets suppressed, NAD+ rises, and tau pathology is attenuated.

This is tissue-specific regulation at its most elegant — and most frustrating for anyone who assumed a one-size-fits-all NAD+ strategy. The brain has its own NAD+ economy, and CD38 is the tax collector.

The NR vs. NMN Debate: Settled (Sort Of)#

The supplement community has been arguing about NR versus NMN for the better part of a decade. A randomized, placebo-controlled trial published in Nature Metabolism (2026) by Christen and colleagues finally put them head-to-head in 65 healthy humans over 14 days^[3].

The result: NR and NMN comparably increased circulatory NAD+ concentrations. Nicotinamide (Nam) did not.

But here's the part the NMN crowd won't love — and the NR crowd won't love either. Neither compound appears to boost NAD+ directly in whole blood ex vivo. The actual mechanism involves gut microbial conversion of both NR and NMN to nicotinic acid (NA), which then drives NAD+ synthesis through the Preiss–Handler pathway. Nicotinic acid — plain old niacin's active form — was the potent NAD+ booster in whole blood, not NMN or NR themselves.

Look, the NMN crowd is going to love the headline — "NMN works!" — and they should, just not for the reasons they think. Your gut bacteria are doing the real work. Which means gut health isn't a nice-to-have for NAD+ optimization; it's a prerequisite.

Fasting, Redox Shifts, and the Brain's Metabolic Flexibility#

Jamerson and Bradshaw (2026), in a thorough review published in Frontiers in Aging Neuroscience, examined how brain NAD+/NADH and NADPH/NADP+ ratios shift with aging and dietary restriction^[2]. Their analysis used metabolite-pair ratios as redox indicators across multiple datasets.

The key finding: fasting caused universal reductive shifts in brain cytoplasmic NAD+/NADH, NADPH/NADP+, and mitochondrial NAD+/NADH. Critically, this reductive shift from fasting was opposite to what ketone ester supplementation or ketogenic diets produce — which cause an oxidative shift in cytoplasmic NAD+/NADH.

This matters for protocol design. Intermittent fasting and exogenous ketones aren't metabolically equivalent in the brain, even though both are sold under the same "metabolic health" umbrella. They push brain redox in different directions. The review argues that cyclic metabolic switching — the alternation between fed and fasted states — is what drives neuroprotection, not a static state in either direction.

SIRT2: The Master Inflammation Switch#

The sirtuin family keeps getting more interesting. A 2025 study in Aging Cell demonstrated that SIRT2-deficient mice showed dramatically increased inflammation across multiple tissues, including the hippocampus, alongside accelerated tissue function decline^[4]. The inverse was also true: NAD+ boosting with compound 78c suppressed aging-associated inflammation and improved tissue function in 24-month-old mice after just 2 months of treatment.

SIRT2 appears to function as a master regulator of aging-associated inflammation, suppressing STING signaling, reducing CD68+ macrophage infiltration, and maintaining tissue integrity. In the hippocampus specifically, SIRT2 deficiency elevated pro-inflammatory gene expression — the kind of chronic, low-grade neuroinflammation that precedes neurodegeneration by years.

Separately, Lin et al. (2025) showed that NMN reversed neurodegeneration in D-galactose-treated mice via Sirt1/AMPK/PGC-1α activation, reducing cortical and hippocampal apoptosis while simultaneously preserving intestinal barrier integrity^[5]. When the researchers blocked Sirt1 with the inhibitor Ex527, the neuroprotective effects disappeared — confirming Sirt1 dependency.

And then there's the broader landscape. Bai et al. (2025), in Trends in Pharmacological Sciences, reviewed all seven sirtuin isoforms in Alzheimer's pathology^[6]. The picture is nuanced: SIRT1 and SIRT3 are largely protective, SIRT2's role is dual and context-dependent (it can be neuroprotective or neurotoxic depending on the inflammatory milieu), and SIRT4, SIRT5, and SIRT7 have isoform-specific mechanisms that are only beginning to be characterized.

I'm less convinced by the blanket "activate all sirtuins" messaging that pervades the longevity space. The data clearly shows these enzymes have opposing effects in different contexts. SIRT2 inhibition has shown benefits in some neurodegeneration models while SIRT2 activation reduces inflammation in others. Context is everything.

COMPARISON TABLE#

THE PROTOCOL#

Based on the current evidence, here's how I'd approach a brain NAD+/sirtuin optimization protocol. A few caveats: optimal human dosing for neuroprotection specifically is not yet established, and most mechanistic data comes from mouse models. Proceed accordingly.

Step 1: Choose your NAD+ precursor — and stop overthinking it. NR or NMN both work comparably for raising circulatory NAD+, per the Nature Metabolism trial^[3]. A daily dose of 250–500 mg of either is a reasonable starting point. Take it in the morning to align with circadian NAD+ rhythms.

Step 2: Prioritize gut microbiome health. Since NR and NMN depend on microbial conversion to nicotinic acid for their NAD+-boosting effect, a compromised microbiome may blunt your response. Include prebiotic fiber (10–15 g/day from diverse sources), fermented foods, and consider a broad-spectrum probiotic. If you've recently completed antibiotics, delay starting NAD+ precursors until gut recovery.

Step 3: Implement time-restricted eating (16:8 or 18:6). The Bradshaw review indicates that cyclic metabolic switching — not constant fasting — drives the neuroprotective reductive shifts in brain redox^[2]. Aim for a consistent feeding window. I personally do 18:6 and the cognitive clarity during extended fasts is noticeable, though I'll be honest — that's n=1 and I can't separate placebo.

Step 4: Support circadian rhythm integrity. The REV-ERBα findings from Lee et al. make circadian alignment non-negotiable^[1]. REV-ERBα activity is light-entrained. Morning sunlight exposure (10–20 minutes within an hour of waking), consistent sleep-wake timing, and elimination of late-night blue light all support the circadian regulation of brain NAD+ metabolism.

Step 5: Add a sirtuin-supporting exercise protocol. Endurance exercise activates both SIRT1 and SIRT3 via AMPK phosphorylation and PGC-1α signaling — the same pathway NMN activates in mouse models^[5]. Three to four sessions per week of zone 2 cardio (30–45 minutes) plus one to two high-intensity sessions provides the metabolic stress that upregulates sirtuin expression.

Step 6: Monitor and adjust. If available, track whole-blood NAD+ levels via commercial testing (several companies now offer this). Reassess every 90 days. HRV optimization can serve as an accessible proxy for autonomic and inflammatory status — aim for a consistent upward trend in resting HRV, which correlates with reduced systemic inflammation.

What is the difference between NR and NMN for brain health?#

In the first direct human comparison, NR and NMN raised circulatory NAD+ concentrations comparably over 14 days^[3]. Both appear to work via gut microbial conversion to nicotinic acid rather than through direct cellular uptake. For brain health specifically, neither has been tested in long-term human cognitive outcome trials — so the honest answer is we don't yet know if one is superior for neuroprotection.

How does CD38 affect NAD+ levels in the aging brain?#

CD38 is an NAD+-consuming enzyme that increases with age and inflammation, effectively draining the brain's NAD+ reserves. The Lee et al. study in Nature Aging identified that in astrocytes, the circadian receptor REV-ERBα indirectly promotes CD38 activity by repressing its suppressor NFIL3^[1]. When astrocytic REV-ERBα was deleted in mice, CD38 was suppressed, brain NAD+ increased, and tau pathology was prevented. CD38 inhibition is currently a preclinical target only — no approved human therapeutics exist yet.

Why does intermittent fasting affect brain NAD+ differently than a ketogenic diet?#

Fasting produces a reductive shift in brain cytoplasmic NAD+/NADH, while ketogenic diets and ketone esters cause an oxidative shift in the same compartment^[2]. They're pushing the same metabolic lever in opposite directions. The Bradshaw review suggests that the cycling between states — not a fixed metabolic state — is what produces neuroprotective benefits. This is why intermittent fasting, with its inherent on-off cycling, may offer distinct advantages over continuous ketosis.

Who should consider NAD+ supplementation for cognitive longevity?#

Based on current evidence, adults over 40 — when NAD+ decline accelerates — stand to benefit most. Individuals with family histories of Alzheimer's disease, those experiencing subjective cognitive decline, or anyone with documented chronic low-grade inflammation should discuss NAD+ precursor supplementation with a clinician. However, large-scale human trials demonstrating cognitive endpoint improvements are still lacking.

What role do sirtuins play in Alzheimer's disease specifically?#

Sirtuins modulate multiple AD-relevant pathways: amyloid-β clearance, tau phosphorylation, neuroinflammation, and mitochondrial function^[6]. SIRT1 is broadly neuroprotective, enhancing autophagy pathways that clear toxic protein aggregates. SIRT2 has a dual role — context-dependent effects that can be either protective or harmful. SIRT3 protects mitochondrial efficiency in neurons. The less-studied isoforms (SIRT4, 5, 7) show emerging but inconsistent roles. No sirtuin-targeting drug has reached clinical approval for AD.

VERDICT#

Score: 7.5/10

The mechanistic data here is genuinely exciting — particularly the Lee et al. astrocyte CD38 finding, which reframes how we think about brain-specific NAD+ regulation. The Nature Metabolism head-to-head trial settles a long-running supplement debate and introduces the gut microbiome as a critical variable that most NAD+ users are ignoring. The SIRT2 inflammation data adds another compelling layer.

But here's my pushback: almost everything actionable still comes from mouse models. The human RCT measured blood NAD+, not brain NAD+, not cognitive outcomes, not disease progression. We're inferring brain effects from circulatory data and rodent neuroscience. That's not nothing — these are well-designed studies in top-tier journals — but it's not the evidence base I'd need to make strong claims about preventing Alzheimer's in humans. The protocol I outlined above is reasonable, low-risk, and grounded in the best available data. Just don't mistake "promising" for "proven."